The healthcare industry is founded on the idea that as diseases become more advanced and difficult to treat, companies responsible for the development of treatment options will work hard to find a possible cure. Given that the world’s population is consistently increasing, aging, and resources are diminishing, access to quality healthcare is something crucial to the wellness of every living person. This in turn, presents a dire need for healthcare companies on a global scale.
It’s no secret that technology has facilitated access and directly helped meet consumer demands in a multitude of industries. Healthcare has become the latest market to take full advantage of this trend as innovation has begun to disrupt the market in a large way. With the demand for healthcare products rising, the need for novel technology and innovative drugs rises as well. This in turn, has investors seeking opportunities in healthcare stocks.
Premier Health Group, Inc. (PHGRF) (PHGI) announced it is growing its development team at Cloud Practice Inc. to support its focus on digitizing healthcare by hiring four new full-time employees, three Web Software Developers and one User Interface/User Experience Designer to support the build out of its patient centric platform and mobile app – a beta version of which will be available by end of Q2, according to the company.
“The future of healthcare is digitally driven and this strategic investment in growing Cloud Practice’s team will enable us to fast-track the build out our app – a much-needed technology innovation in healthcare,” said Dr. Essam Hamza, CEO. “Our goal is to tackle the accessibility bottlenecks by putting the power in the hands of patients. Not only will our app enable patients’ access to their health care providers, but also allow for cohesive patient care by coordinating and connecting all members of their health care team.”
The new patient portal will provide Cloud Practice clients with additional services which will be provided via a SaaS (software-as-a-service) model, allowing for new recurring revenues that are scalable. The services will initially be extended to the 290 clinics in Premier Health’s ecosystem, a number which the Company is actively growing, then will eventually go direct to consumer later this year.
Premier Health annouced expansion plans to formally enter the cannabis clinic space and has been in discussions with Canadian ACMPR-Licensed Producers in order to partner with a, or multiple, Licensed Producers. The company is also in the process of closing on two operating pharmacies in Metro Vancouver, with a combined revenue of approximately $6 million (FY 2018) and anticipates the acquisition to close in or about Q2 2019 and recently announced a partnership with a major online healthcare company in China, 360 Health enabling the Premier’s healthcare team to connect with patients virtually in China to provide second opinion services.
NanoViricides, Inc. (NNVC) announced that it has reached an agreement on the terms of the license for the drug development against VZV, the virus that causes chickenpox in children and shingles in adults. The company and licensor TheraCour Pharma Inc. agreed that TheraCour will not receive any payment upon signing of a license agreement and no cash but 500,000 shares of NanoViricides Series A Preferred Stock as a milestone payment when an investigational New Drug Application becomes effective.
If NanoViricides completes Phase I human clinical trials, TheraCour will receive a milestone payment of $1.5 million in cash and, Phase II human clinical trials are completed, TheraCour will receive a milestone payment of $2.5 million in cash. Other compensation terms will be consistent with the company’s existing license agreements with TheraCour, including a 15% royalty on sales.
NanoCiricides is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company is developing drugs against several viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
Zynerba Pharmaceuticals, Inc. (ZYNE) announced that the U.S. Patent and Trademark Office has issued US Patent No. 10,213,390, titled “Treatment of Fragile X Syndrome with Cannabidiol” which includes claims directed to methods of treating Fragile X Syndrome by administering a therapeutically effective amount of synthetic or purified cannabidiol. This new patent, which expires in 2038, is part of an expanding intellectual property portfolio covering Zynerba’s lead pipeline candidate, ZYN002 Transdermal CBD gel.
The issuance of this patent comes as enrollment is progressing in the company’s CONNECT-FX study evaluating the efficacy and safety of ZYN002 in three through 17-year old FXS patients with full mutation of the FMR1 gene. The primary endpoint is the change from baseline to the end of the treatment period in the Aberrant Behavior Checklist-Community FXS Specific (ABC-CFXS) Social Avoidance subscale.
Clinical investigative sites are enrolling patients in the United States, Australia, and New Zealand. Patients who have completed the double-blind phase are now enrolling into the 12-month open label phase. The Company expects to report top line data in the second half of 2019.
This blog is an affiliate of MIDAM VENTURES LLC. Pursuant to an agreement between Midam and Premier Health Group Inc., Midam was hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. Midam were paid $300,000 (CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). Midam owns zero shares of Premier Health Group Inc., which Midam purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 Midam plans to sell the “500,000” shares of Premier Health Group Inc. that Midam holds currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Midam may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click here for full Midam disclaimer.